Osaka, Japan

Naotake Kobayashi

USPTO Granted Patents = 12 


 

Average Co-Inventor Count = 7.7

ph-index = 2

Forward Citations = 52(Granted Patents)


Location History:

  • Shiga-ken, JP (2003)
  • Osaka, JP (2012 - 2023)

Company Filing History:


Years Active: 2003-2023

Loading Chart...
Loading Chart...
Loading Chart...
12 patents (USPTO):

Title: Naotake Kobayashi: Innovator in Pharmaceutical Chemistry

Introduction

Naotake Kobayashi is a prominent inventor based in Osaka, Japan. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of novel compounds with therapeutic applications. With a total of 12 patents to his name, Kobayashi's work has had a substantial impact on drug development.

Latest Patents

Kobayashi's latest patents include innovative compounds such as bicyclic nitrogen-containing heterocyclic derivatives. These compounds exhibit antagonistic activity for the P2X receptor, which is crucial in various physiological processes. The pharmaceutical compositions derived from these compounds hold promise for treating conditions related to P2X receptor activity.

Career Highlights

Throughout his career, Naotake Kobayashi has worked with notable companies, including Shionogi & Company Limited. His expertise in pharmaceutical chemistry has allowed him to contribute to the development of important therapeutic agents. His work is characterized by a commitment to advancing medical science through innovative research.

Collaborations

Kobayashi has collaborated with esteemed colleagues such as Kazuo Ueda and Naohiro Itoh. These partnerships have fostered a collaborative environment that enhances the quality and impact of their research.

Conclusion

Naotake Kobayashi's contributions to pharmaceutical chemistry and his innovative patents underscore his role as a leading inventor in the field. His work continues to influence the development of new therapeutic agents, showcasing the importance of innovation in healthcare.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…